Payment overview · 2025
General Payments
$566.84
8 reported records · 3 companies
Healthcare provider profile · identity verified
Mai Yousef, MD
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1437119914
Verified facts
What the public records show
CMS Open Payments records show Mai Yousef, MD received $566.84 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $357.67 | 63.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.62 | 27.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.55 | 9.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.84 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $232.67 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.00 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.55 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.55 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 71 |
| Lisinopril | Lisinopril | 253 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 55 |
| Losartan Potassium | Losartan Potassium | 218 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 181 | 41 |
| Metformin Hcl | Metformin Hcl | 166 | 40 |
| Simvastatin | Simvastatin | 154 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 33 |
| Sertraline Hcl | Sertraline Hcl | 140 | 33 |
| Omeprazole | Omeprazole | 139 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 32 |
| Potassium Chloride | Potassium Chloride | 122 | 39 |
| Donepezil Hcl | Donepezil Hcl | 120 | 18 |
| Furosemide | Furosemide | 120 | 36 |
| Atenolol | Atenolol | 114 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 36 |
| Eliquis | Apixaban | 109 | 26 |
| Gabapentin | Gabapentin | 108 | 25 |
| Trazodone Hcl | Trazodone Hcl | 98 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 31 |
| Alendronate Sodium | Alendronate Sodium | 94 | 37 |
| Spironolactone | Spironolactone | 94 | 24 |
| Jardiance | Empagliflozin | 89 | 17 |
| Alprazolam | Alprazolam | 88 | 27 |
| Famotidine | Famotidine | 87 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 78 | 78 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Ozempic | Semaglutide | 77 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 17 |
| Metformin Hcl Er | Metformin Hcl | 73 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 16 |
| Meloxicam | Meloxicam | 65 | 32 |
| Montelukast Sodium | Montelukast Sodium | 64 | 15 |
| Carvedilol | Carvedilol | 62 | 16 |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Allopurinol | Allopurinol | 56 | 17 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Valsartan | Valsartan | 51 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 21 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Glipizide Er | Glipizide | 49 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 40 | 40 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 33 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 14 |
| Ramipril | Ramipril | 29 | suppressed |
| Prednisone | Prednisone | 28 | 16 |
| Baclofen | Baclofen | 26 | 14 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Glipizide | Glipizide | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | 11 |
| Nystatin | Nystatin | 22 | 12 |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Diazepam | Diazepam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Cephalexin | Cephalexin | 17 | 16 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 16 |
| Colchicine | Colchicine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.84 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error